DxNA, a privately owned St. George, Utah-based molecular diagnostics firm, will acquire privately held Flagstaff, Ariz.-based Pathogene for an undisclosed amount under an agreement inked by the companies this week.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.
Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.
The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.
Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."